FIGURES AND TABLES

Figure 1.

Schematic presentation of the IGFBP5 gene and the locations of the single-nucleotide polymorphisms. White boxes, UTR; black boxes, coding region.

Figure 2.

Associations of the IGFBP5 markers rs9341234 (a and b), rs3276 (c and d) and rs11575134 (e) with the concentrations of serum adiponectin at baseline in the Finnish Diabetes Preventions Study. All results are adjusted with age, body mass index and gender. Data are meanss.e.m.

Figure 3.

Association of IGFBP5 marker rs11575134 with the concentration of plasma adiponectin in (a) normoglycemic men, (b) men with impaired fasting glucose, (c) men with impaired glucose tolerance and (d) men with T2DM in METSIM study. Data are meanss.e.m.

Figure 4.

Correlations between gene expression of IGFBP5 and adiponectin in adipose tissue at baseline of the FUNGENUT and GENOBIN studies in (a) all subjects, (N=115; P<0.001, r ²=0.368) (b) in women (N=61; P=0.001, r ²=0.425, corrected with fat mass) and (c) in men (N=54; P=0.291, r ²=0.291). Gene expression data are represented relative to the endogenous control cyclophilin A1.

Table 1 - Baseline characteristics of the individuals of the FUNGENUT and GENOBIN studies. Data are meanss.d.

Table 2 - The pairwise linkage disequilibrium values (D' and r ²-values) of the IGFBP5 SNPs in the participants of the Finnish DPS.

Table 3 - Association of IGFBP5 SNPs with concentrations of serum adiponectin (g ml^-1) in the Finnish Diabetes Prevention Study divided according to genotypes of IGFBP5 .